fbpx

ARA 290

$199.00$659.00

ARA-290 is used for the treatment of neuropathy in diabetics, however emerging data suggests that COVID patients with neuropathy, chronic inflammation and fatigue are finding significant benefits. Our COVID Long Hauler treatment protocol one is focused on powerful anti-inflammatory drugs and reduction in oxidative stress.

Clear
Want a discount? Become a member by purchasing Peptide Club!

SKU: SQ9900013-1 Category: Tags: , , , ,

ARA-290 is used for the treatment of neuropathy in diabetics, however emerging data suggests that COVID patients with neuropathy, chronic inflammation and fatigue are finding significant benefits. ARA-290 is  a nonhematopoietic peptide designed from the structure of erythropoietin that interacts selectively with the innate repair receptor which mediates tissue protection. ARA-290 has shown efficacy in preclinical and clinical studies of metabolic control and neuropathy. ARA-290 is a small peptide that activates the innate repair receptor to induce anti-inflammatory and tissue repair mechanisms.

  • Activates Repair Mechanisms
  • Accelerates Wound Healing
  • Helps Repair Nerve Damage
  • Regulates Blood Sugar Levels

Formulations:

  • ARA-290 [2mg/mL] (SQ Injection) 3mL Vial
  • ARA-290 [2mg/mL] (SQ Injection) 4mL Vial
  • ARA-290 [2mg/mL] (SQ Injection) 5mL Vial
  • ARA-290 [8mg/mL] (SQ Injection) 3mL Vial
  • ARA-290 [8mg/mL] (SQ Injection) 4mL Vial
  • ARA-290 [8mg/mL] (SQ Injection) 5mL Vial

Dosing:

  • 4mg daily x 30 days subcutaneous injection

The Long Haul COVID-19 Syndrome (LHCS or Long Hauler) is an often debilitating syndrome characterized by a multitude of symptoms such as prolonged malaise, headaches, generalized fatigue, sleep difficulties, smell disorder, decreased appetite, painful joints, dyspnea, chest pain and cognitive dysfunction. The incidence of symptoms after COVID-19 varies from as low as 10% to as high as 80%. LHCS is not only seen after the COVID-19 infection but it is being observed in some people that have received vaccines (likely due to monocyte activation by the spike protein from the vaccine). A puzzling feature of the LHCS syndrome is that it is not predicted by initial disease severity; post-COVID-19 frequently affects mild-to-moderate cases and younger adults that did not require respiratory support or intensive care.

 

Limited data is available on LHCS and current treatment is focused on symptoms with multiple different medications and supplements. There is no guarantee that the treatment offered by Mobile Care or any provider will reduce or cure LHCS. Please call or book a free consult online.

Formulation

ARA-290 [2mg/mL] (SQ Injection) 3mL Vial, ARA-290 [2mg/mL] (SQ Injection) 4mL Vial, ARA-290 [2mg/mL] (SQ Injection) 5mL Vial, ARA-290 [8mg/mL] (SQ Injection) 3mL Vial, ARA-290 [8mg/mL] (SQ Injection) 4mL Vial, ARA-290 [8mg/mL] (SQ Injection) 5mL Vial

Reviews

There are no reviews yet.

Only logged in customers who have purchased this product may leave a review.